Efficacy of Delgocitinib for Dermatomyositis
- Conditions
- DermatomyositisM339
- Registration Number
- JPRN-jRCTs031230077
- Lead Sponsor
- Watanabe Tomoya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 21
(1) Men and women 18 years of age or older at the time of enrollment
(2) Patients diagnosed with dermatomyositis
(3) Patients with stable interstitial pneumonia or myositis after systemic therapy with oral steroids or immunosuppressive drugs
(4) Patients with residual skin rash after systemic therapy with oral steroids or immunosuppressive agents, patients with flare-ups of skin rash after tapering off of oral steroids or immunosuppressive agents, or patients with skin rash alone without myositis or interstitial pneumonia and not eligible for systemic therapy
(5) Patients in (4) who have a skin rash refractory to treatment despite standard therapy*.
(6) Patients who are able to walk independently and answer questionnaires
(7) Patients who give written consent to participate in this study.
(1) Patients with a history of hypersensitivity to delgocitinib
(2) Women who are pregnant, lactating, may be pregnant, or wish to become pregnant during the treatment period
(3) Patients with severe skin infections
(4) Patients with dermatomyositis who have anti-ARS antibody
(5) Patients who are judged by doctor to be inappropriate as subjects
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method